ENGN 股价走势图
ENGN 股票价格预测
enGene Therapeutics Inc
$1.72
-80.56%
$-7.13
收盘价：May 07, 16:00:00 GMT-4
$1.72
0.03%
$0
盘后：May 07, 19:43:02 GMT-4
返回
enGene Therapeutics Inc (ENGN) 股票价格预测
关键数据
前收盘价
$8.85
开盘价
$2.14
当日区间
$1.7 - $2.24
52周范围
$1.72 - $12.25
交易量
23.4M
平均成交量
401.2K
股息收益率
--
每股收益（TTM）
-2.25
市值
$115.2M
什么是 ENGN？
enGene Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. The company is headquartered in Saint-Laurent, Quebec and currently employs 45 full-time employees. The company went IPO on 2021-12-10. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).
